Literature DB >> 21901239

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.

A M Gallagher1, E Setakis, J M Plumb, A Clemens, T-P van Staa.   

Abstract

Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarin-treated (with at least 3 INR measurements) and 10,449 patients not treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA2DS2-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901239     DOI: 10.1160/TH11-05-0353

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  78 in total

1.  Stroke prevention in atrial fibrillation: we can do better.

Authors:  Matt Kearney; Matthew Fay; David A Fitzmaurice
Journal:  Br J Gen Pract       Date:  2016-02       Impact factor: 5.386

2.  Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.

Authors:  Nur A Rahmat; Gregory Y H Lip
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

Review 3.  Drug adherence in patients taking oral anticoagulation therapy.

Authors:  Sebastian Ewen; Volker Rettig-Ewen; Felix Mahfoud; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2013-09-03       Impact factor: 5.460

4.  Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.

Authors:  Laurent Lafarge; Fouzi Khayi; Anis Bel-Kamel; Nicolas Charhon; Laura Sarfati; Benoit Falquet; Michel Ducher; Laurent Bourguignon
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

5.  Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).

Authors:  Matthieu Plichart; Gilles Berrut; Nathalie Maubourguet; Claude Jeandel; Jean-Paul Emeriau; Joël Ankri; Hélène Bouvier; Geneviève Ruault; Olivier Hanon
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

6.  Use of novel oral anticoagulants in patients with heart failure.

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

7.  Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials.

Authors:  H L Tang; W L Shi; X G Li; T Zhang; S D Zhai; H G Xie
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

Review 8.  Safety and efficacy of new anticoagulants in patients with heart failure.

Authors:  Ron Pisters; Gregory Y H Lip
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 9.  Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.

Authors:  Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

10.  A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin.

Authors:  Daniela Poli; Emilia Antonucci; Sophie Testa; Gregory Yoke Hong Lip
Journal:  Intern Emerg Med       Date:  2014-03-21       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.